)
)
Single Cell Multiomic Profiling Reveals Mechanisms of Resistance in Triple Negative Breast Cancer
-
Neoadjuvant chemotherapy (NAC) remains the mainstay of treatment for triple negative breast cancer (TNBC) patients. Although addition of immunotherapy to NAC has improved outcome for some patients, many patients show resistance to NAC, leading to treatment failure and disease progression.
-
We profiled a cohort of treatment naïve TNBCs encompassing resistant and sensitive patients using matched multiomic single cell spatial profiling and identify subclonal niches that were associated with response to NAC.
-
We successfully validated these NAC response associated gene signatures in independent patient cohorts and also confirm their stabilisation in post-NAC patient samples revealing new targetable biology.
